FUNDAMENTALS · Fundamentals · TW Healthcare

Chi Sheng Pharma & Biotech (4111) Fundamentals 2026 — P/E 9.9x, Revenue Analysis | SniperIQ

Chi Sheng Pharma & Biotech (4111) is a TW-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of NT

.8B, trading at NT
0.00 on the TWO. This SniperIQ fundamentals page covers Chi Sheng Pharma & Biotech's valuation (P/E 9.9x, P/B 1.3x), profitability (net margin 12.7%), revenue (NT
.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
.8B
P/E (TTM)9.9x
Net Margin12.7%
Revenue (FY25)NT
.4B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Chi Sheng Pharma & Biotech's market cap?

Chi Sheng Pharma & Biotech (4111) has a market capitalization of approximately NT

.8B, trading at NT
0.00 on the TWO. Market cap moves with the live share price.

What is Chi Sheng Pharma & Biotech's P/E ratio?

Chi Sheng Pharma & Biotech's trailing twelve-month P/E ratio is 9.9x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Chi Sheng Pharma & Biotech?

Chi Sheng Pharma & Biotech runs a net profit margin of 12.7%, a gross margin of 38.9%, and an operating margin of 15.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Chi Sheng Pharma & Biotech generate?

Chi Sheng Pharma & Biotech reported revenue of NT

.4B for fiscal year 2025, with net income of NT
64M and earnings per share (EPS) of 2.75. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Chi Sheng Pharma & Biotech pay a dividend?

Chi Sheng Pharma & Biotech offers a trailing dividend yield of about 3.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Chi Sheng Pharma & Biotech financially healthy?

Chi Sheng Pharma & Biotech carries a debt-to-equity ratio of 0.04x and a current ratio of 2.26x, with a market beta of 0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Chi Sheng Pharma & Biotech a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Chi Sheng Pharma & Biotech (4111) the key facts are: market cap NT

.8B, P/E 9.9x, revenue NT
.4B, 52-week range 28.85-32.9. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Chi Sheng Pharma & Biotech's full fundamentals live

Get Chi Sheng Pharma & Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.